IGG4 RELATED DISEASE

This phase 3 study tests whether the oral drug rilzabrutinib can prevent disease flares in adults with active IgG4-related disease, a rare condition causing swelling and organ damage. About 124 participants will receive either rilzabrutinib or a placebo for 52 weeks, alongside st…

This study is testing a drug that blocks a key immune signal (JAK1) to see if it can help people with three rare inflammatory diseases: Behçet's disease, myositis, and IgG4-related disease. The goal is to reduce disease activity and lower the need for long-term steroids, which ha…

This phase 2 trial tests a new treatment called anti-BCMA-CD19 CAR-T cells for adults with IgG4-related disease that hasn't improved with standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target and attack disease-causing cells. Nine partici…

This early-stage trial tests a new treatment called ACE1831 for people with IgG4-related disease, a rare condition where the immune system attacks the body, causing swelling and organ damage. ACE1831 is made from healthy donor cells and given as an infusion. The study will check …

This study tests a drug called efgartigimod in 5 adults with IgG4-related disease, a condition that causes swelling in glands and organs. Participants receive weekly injections for 12 weeks. The goal is to see if the drug reduces swelling in the tear glands, saliva glands, or pan…

This study tests whether adding lenalidomide to standard prednisone treatment can better control active IgG4-related disease, a rare condition causing swelling and damage in organs. About 198 adults will receive either low-dose lenalidomide plus prednisone, higher-dose lenalidomi…

This study compares a new imaging tracer, [18F]-AlF-FAPI-74, with the standard [18F]-FDG in PET/CT scans for people with hard-to-diagnose inflammatory conditions like fever of unknown origin, IgG4-related disease, and axial spondyloarthritis. Researchers aim to see if the new tra…